Onconova Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, focused on identifying and advancing innovative therapeutic solutions for oncological diseases. The company's pipeline currently highlights two primary drug candidates undergoing clinical trials: 1. Narazaciclib (ON 123300): This is a multi-targeted kinase inhibitor being evaluated in Phase I studies. It targets both solid tumors and hematological malignancies, with assessments as a standalone agent or in combination with other anti-cancer treatments. 2. Oral Rigosertib: This compound is in Phase I/IIa trials. It is being investigated, either alone or alongside a PD-1 inhibitor, for the treatment of progressive non-small cell lung cancer that carries K-Ras mutations. Additionally, Onconova is backing a Phase Ib/II investigator-sponsored study (ISS) examining rigosertib as a monotherapy for patients suffering from advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. Rigosertib is also undergoing preclinical development for COVID-19, available in both intravenous and oral formulations. To support its endeavors, Onconova Therapeutics has forged several strategic alliances, including a licensing agreement with SymBio Pharmaceuticals Limited. It also holds a comprehensive license, development, and commercialization pact with Pint International SA. Furthermore, the company has a collaborative licensing deal with HanX Biopharmaceuticals, Inc. specifically for the development, regulatory registration, and market release of narazaciclib. Established in 1998, Onconova Therapeutics, Inc. maintains its corporate headquarters in Newtown, Pennsylvania.